Travere Therapeutics
TVTX
120 hedge funds and large institutions have $845M invested in Travere Therapeutics in 2017 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 40 increasing their positions, 44 reducing their positions, and 10 closing their positions.
1,006% more call options, than puts
Call options by funds: $16.1M | Put options by funds: $1.45M
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
6% more funds holding
Funds holding: 113 → 120 (+7)
9% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 44
5.52% less ownership
Funds ownership: 107.54% → 102.02% (-5.5%)
18% less capital invested
Capital invested by funds: $1.03B → $845M (-$183M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$8.96M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$3.17M |
| 3 |
D.E. Shaw & Co
New York
|
+$3.1M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$1.85M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.2M |
| 2 |
Jennison Associates
New York
|
-$9.89M |
| 3 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
-$5.66M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.33M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$3.63M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
JCM
126
Jafra Capital Management
New York
| – | -$329K | -13,226 | Closed |
|
127
Squarepoint
New York
| – | -$299K | -12,030 | Closed |
|
|
CCIA
128
Campbell & Co Investment Adviser
Baltimore,
Maryland
| – | -$249K | -10,017 | Closed |
|
|
TI
129
Trexquant Investment
Stamford,
Connecticut
| – | -$203K | -8,154 | Closed |
|
|
QT
130
Quantbot Technologies
New York
| – | -$66K | -2,683 | Closed |
|
TVTX Hedge Fund Activity: Q4 2017 in Review
120 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q4 2017, worth a combined $845M — down 18% from $1.03B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new TVTX positions and 10 closed out — a net gain of 7 holders — while 40 added to existing stakes and 44 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $8.96M. The largest seller was Fidelity Investments, cutting an estimated $11.2M.
- 120 institutional investors held Travere Therapeutics (TVTX) as of Q4 2017, up from 113 in Q3 2017.
- Funds reported $845M of Travere Therapeutics stock for Q4 2017, down 18% quarter-over-quarter.
- 17 funds opened new Travere Therapeutics positions in Q4 2017 and 10 closed out, a net change of +7 holders.
- The largest Travere Therapeutics buyer in Q4 2017 was Point72 Asset Management, an estimated $8.96M added.
- The largest Travere Therapeutics seller in Q4 2017 was Fidelity Investments, an estimated $11.2M sold.
Based on aggregated 13F filings for Q4 2017.